Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 64
Filter
1.
Laboratory Diagnostics Eastern Europe ; 11(4):420-437, 2022.
Article in Russian | Scopus | ID: covidwho-2164705

ABSTRACT

Introduction. Immunocompromised individuals, such as kidney and liver recipients, are at high risk for a severe course of COVID-19, which explains the special interest in this category of patients in conditions of high incidence of this infection and mass vaccination with available vaccines. Purpose. To study the characteristics of humoral post-infection and post-vaccination immunity to SARS-CoV-2 in kidney and liver recipients based on qualitative and quantitative serotesting. Materials and methods. The study of characteristics of post-infection immunity was carried out in the group of immunocompromised individuals (n=213) including kidney (n=177) and liver (n=26) recipients with PCR confirmed COVID-19, while the study of post-vaccination immunity was carried out in the group of kidney (n=56) and liver (n=12) recipients immunized with Sputnik V (Russia) or Vero Cell (China). In comparative studies, a simple randomized sample was used of immunocompetent patients who recovered from COVID-19 (n=163), corresponding in age and gender to that of the recipients examined, as well as a convenient sample of immunocompetent individuals vaccinated with Sputnik V (n=257) and Vero Cell (n=160). Serotesting for the detection of IgG to S and N proteins of SARS-CoV-2 was carried out by ELISA. Reliable intervals for proportions were calculated using the Wald method. The significance of the detected differences was assessed by the χ2 (chi-square) method. Results. The paper presents data on comparative serological testing of kidney and liver recipients recovered from COVID-19. The detection rate of post-infectious IgG to N and S proteins of SARS-CoV-2 was found to be 88.1% in the group of kidney recipients, 91.3% in the group of liver recipients, and 91.7% in the group of immunocompetent individuals. At the same time, the proportion of N protein seropositive subjects in all groups of observation was lower in comparison with that to S protein, with a significant difference in the group of kidney recipients (59.9% and 86.4%, respectively, p<0.001). The overall dynamics of the decrease in proportion of seropositive individuals during the observation period up to 12 months from the onset of clinical manifestations of infection in both groups of recipients and in the group of immunocompetent individuals had common patterns, however, seroprevalence rates for IgG to N protein significantly differed over time (9–12 months from the onset of the disease) and were much higher in the group of immunocompetent individuals (p<0.001). Despite the presence of general patterns of post-infection antibody response formation, seroprevalence rates to SARS-CoV-2 and the duration of post-infection antibody persistence were slightly lower in the group of kidney recipients than in the group of liver recipients and in immunocompetent individuals. The immunological efficacy of vaccination (the proportion of individuals with post-vaccination antibodies) in the group of kidney recipients was significantly lower (p<0.001) than in the group of immunocompetent patients after both Sputnik V (68.0% and 98.8%, respectively) and Vero Cell (58.1% and 95.0%, respectively) immunization. In liver transplant recipients, there were no significant differences with immunocompetent individuals in terms of post-vaccination response. Conclusion. The data obtained indicate certain differences in characteristics of post-infection and post-vaccination antibody response due to patients' immune status. © 2022, Professionalnye Izdaniya. All rights reserved.

2.
Immunologiya ; 43(5):583-592, 2022.
Article in Russian | EMBASE | ID: covidwho-2164675

ABSTRACT

Introduction. Despite widespread vaccination against COVID-19 worldwide, the epidemiological situation remains insufficient. The appearance of mutant forms of SARS-CoV-2 with increased virulence causes new waves of COVID-19 morbidity. The virus variability can cause the reduction of the vaccination effectiveness. In this regard, it is important to study the dynamics of post-vaccination immunity, its features in various population groups, as well as the relationship between post-infectious and post-vaccination immunity. The study continues a series of researches of the features of SARS-CoV-2-specific immunity in COVID-19 convalescents and recipients of the <<Sputnik V>> vaccine. The aim of the study - assessment of the intensity of the SARS-CoV-2-specific immune response in different age groups of people passed COVID-19 and subsequently vaccinated with <<Sputnik V>>. Material and methods. With the help of EIA, the level of IgG antibodies to S-antigen and N-antigen of SARS-CoV-2 was studied in 155 samples of blood sera of individuals (men and women) aged 18 to 70 years who passed COVID-19 and after 6 month of recovery underwent a full course of vaccination with <<Sputnik V>>. Samples from individuals of the following age groups were examined: from 18 to 35, from 35 to 45, from 45 to 55, from 55 to 65, from 65 to 70 years. Results. In all the examined age groups of individuals passed COVID-19 and then vaccinated with <<Sputnik V>>, there was a high level of IgG antibodies to SARS-CoV-2 S-protein (positivity coefficient 8.1 and higher). The level of IgG antibodies to the N-protein in more than half of the cases was lower than positive values among all the subjects. Conclusion. The study showed that individuals passed COVID-19 and then vaccinated with <<Sputnik V>>, regardless of age, have intense post-vaccination humoral immunity. Copyright © 2022 Meditsina Publishers. All rights reserved.

3.
Pediatr Neonatol ; 63(6): 633-641, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-2132061

ABSTRACT

BACKGROUND: Singapore was one of the first countries to begin COVID-19 vaccination with the BNT162b2 vaccine for adolescents aged 12-18 years. This study evaluates the incidence of COVID-19 vaccine related attendances to a Pediatric Emergency Department (PED) to understand post-vaccination health behaviors among adolescents. METHODS: This was a retrospective review of electronic medical records over a 4 month period, from the start of the adolescent vaccination drive to when more than 85% of this group had been fully vaccinated. RESULTS: The incidence of COVID-19 vaccination-related presentations to our PED was 3.1% over 4 months (291 of 9387 PED attendances), with a peak daily incidence of 15.4% (14 of 91 attendances). Presentations were characterized by severity into: severe (3.4%), moderate (7.9%) or mild (88.7%) based on predefined criteria. The most common presenting complaints were chest pain (58.8%), dyspnea (28.2%) and palpitations (22.6%). Hospitalization was required in only 6.2% of attendances. Patients with moderate-severe presentations were 0.7 years older (p = 0.030), more likely to have underlying drug allergies (p = 0.048) and had higher rates of hospitalization (p < 0.005) compared to mild presentations. Despite concerns of cardiac inflammation, chest pain related attendances were less likely to be severe (p < 0.005) with reduced hospitalization need (p = 0.043) compared to other presentations. Investigations beyond clinical assessment comprised 91% of attendances, but abnormalities were only found in 6.4% cases. CONCLUSION: Our study supports current evidence that COVID-19 vaccination is safe amongst adolescents. We highlight the health behaviors among adolescents post-vaccination, which is partly driven by media reports on vaccine side effects and an element of anxiety. While most of the presentations were mild, these can have implications on health resource utilization, particularly in an ongoing pandemic. As healthcare workers, we have an ongoing role to ensure accurate information on vaccine safety is communicated effectively to the public.


Subject(s)
COVID-19 Vaccines , COVID-19 , Adolescent , Child , Humans , BNT162 Vaccine , Chest Pain/chemically induced , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Emergency Service, Hospital , Singapore/epidemiology , Vaccination/adverse effects , Retrospective Studies
4.
Epidemiologiya i Vaktsinoprofilaktika ; 21(5):4-13, 2022.
Article in Russian | Scopus | ID: covidwho-2146371

ABSTRACT

Relevance. During a pandemic, the epidemiological well-being of the population of the whole world depends on the vaccination of each individual person, as cells of the immune layer. Only reliable and open information about adverse events after the use of vaccines, obtained in a timely manner in the process of continuous monitoring, can support the confidence and adherence of the population to vaccination. Aim. To assess the monitoring system for AEFI (Adverse Events Following Immunization) in the Russian Federation and other countries. Materials and methods. A descriptive epidemiological study was conducted with a review of regulatory and methodological documents, forms of federal statistical observation, information from the AIS «DRAID» (Analytical Information System «Department of registration and accounting of infectious diseases» program in Moscow, acts of investigation of post-vaccination complications, which were carried out by specialists from the branches of the Center for Hygiene and Epidemiology in Moscow, sources: eLIBRARU.ru, cyberleninka.ru, information from WHO’s websites, Internet resources for monitoring AEFIs in different countries and websites of manufacturers of COVID-19 vaccines, instructions for vaccines. Conclusion. Thus, it is almost impossible for an epidemiologist working in one of the departments that participates in the monitoring of AEFIs to conduct a full-fledged prospective and retrospective epidemiological analysis and draw unambiguous conclusions about the AEFIs based only on data from open sources and forms of state statistical observation. There is a need for interaction and exchange of information between the subjects of monitoring. © 2022, Numikom. All rights reserved.

5.
Andrologia i Genital'naa Hirurgia ; 23(3):41-47, 2022.
Article in Russian | Scopus | ID: covidwho-2145730

ABSTRACT

Nowadays, the most notable negative effects of SARS-CoV-2 are the pulmonary manifestations as well as cardiovascular system damage. Evaluation of postvaccination changes in the male reproductive system and analysis of their mechanisms seem to be important because of their direct effect on fertility. Thus, it may play a significant role in perspective. Studies based on the application of fluorescence in situ hybridization showed that most acini epithelial cells, as well as some mesenchymal and endothelial cells were positive for SARS-CoV-2 RNA. As for co-expression of the ACE2 cell receptor and the serine protease TMPRSS2, which the virus uses to enter cells, it was also detected in most prostate epithelial and stromal cells. The mechanism of prostate damage in COVID-19 may also be related to dysregulation of the renin-angiotensin system. Increased levels of angiotensin-2 secretion in the prostate in patients with benign prostatic hyperplasia may increase the effect of the virus directly on the cells of the organ. These mechanisms may explain the elevated serum prostatic specific antigen levels in patients with benign prostatic hyperplasia during the active period of COVID-19. Non-specific mechanism of prostate damage is connected with coagulopathy development – thrombosis of venous plexus and hemodynamic disturbances, which can cause secondary damage of parenchyma. There is a definite relationship between the hormonal status of the patient and the severity of the infection – low levels of both testosterone and dihydrotestosterone contribute to the development of severe complications in patients infected with SARS-CoV-2. The possibility of using testosterone drugs in patients with hypogonadism and COVID-19 as an alternative treatment option – to suppress the cytokine storm phenomenon – is being considered. Patients with a history of prostate cancer, with localized prostate cancer in the absence of metastases participated in vaccine studies – among the side effects of vaccination in several cases only regional lymphadenopathy on the injection side of the drug was noted. © 2022 ABV-Press Publishing House. All rights reserved.

6.
J Allergy Clin Immunol Pract ; 2022 Nov 12.
Article in English | MEDLINE | ID: covidwho-2105248

ABSTRACT

BACKGROUND: Common variable immunodeficiency (CVID) is characterized by an impaired post-vaccination response, high susceptibility to respiratory tract infections, and a broad spectrum of non-infectious complications. Thus, patients with CVID may be at high risk of coronavirus disease (COVID-19), and vaccination's role in prevention is questionable. OBJECTIVE: We evaluated the clinical outcomes, safety, and dynamics of humoral and T-cell immune responses induced by the mRNA vaccine BNT162b2 in CVID. METHODS: This prospective observational cohort study focused on the clinical outcomes (proportion of infected patients, disease severity), safety (adverse-event incidence, laboratory-parameter changes), and dynamics of humoral (specific post-vaccination and virus-neutralizing-antibody assessment) and T-cell immune responses (anti-SARS-CoV-2 specific T-cell detection) in 21 patients with CVID after a two-dose administration of BNT162b2. The patients were followed for 6 months. RESULTS: Humoral response was observed in 52% (11/21) of patients at month 1 post-vaccination but continuously decreased to 33.3% (5/15) at month 6. Nevertheless, they had a remarkably lower anti-SARS-CoV-2 neutralizing antibody titer than healthy controls. The T-cell response was measurable in 33% (6/17) of patients with CVID at month 1, and it persisted for the study period. Mild infection occurred in three patients (14.3%) within the follow-up period. The vaccine also exhibited a favorable safety profile. CONCLUSIONS: The BNT162b2 vaccine elicited a measurable antibody response in a high proportion of patients, but it was limited by low titer of the virus-neutralizing antibodies and rapid waning of anti-RBD SARS-CoV-2 specific antibodies. T-cell response was detected in one-third of the patients and remained stable within the follow-up period. Vaccination has favorable safety and clinical-related outcomes in preventing severe COVID-19.

7.
Vaccines (Basel) ; 10(10)2022 Oct 21.
Article in English | MEDLINE | ID: covidwho-2082063

ABSTRACT

Since the introduction of coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccines, there have been multiple reports of post-vaccination myocarditis (mainly affecting young healthy males). We report on four patients with active autoimmune rheumatic diseases (ARDs) and probable or confirmed myocarditis following COVID-19 mRNA vaccination managed at a tertiary hospital in Singapore; we reviewed the literature on post-COVID-19 mRNA vaccination-related myocarditis and ARD flares. Three patients had existing ARD flares (two had systemic lupus erythematosus (SLE), one had eosinophilic granulomatosis polyangiitis (EGPA)), and one had new-onset EGPA. All patients recovered well after receiving immunosuppressants comprising high-dose glucocorticoids, cyclophosphamide, and rituximab. Thus far, only one case of active SLE with myocarditis has been reported post-COVID-19 mRNA vaccination in the literature. In contrast to isolated post-COVID-19 mRNA vaccination myocarditis, our older-aged patients had myocarditis associated with ARD flares post-COVID-19 vaccination (that occurred after one dose of an mRNA vaccine), associated with other features of ARD flares, and required increased immunosuppression to achieve myocarditis resolution. This case series serves to highlight the differences in clinical and therapeutic aspects in ARD patients, heighten the vigilance of rheumatologists for this development, and encourage the adoption of risk reduction strategies in this vulnerable population.

8.
J Pak Med Assoc ; 72(9): 1792-1796, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-2067712

ABSTRACT

OBJECTIVE: To assess adverse effects post-vaccination in healthcare professionals in the first vaccinated group against coronavirus disease-2019. METHODS: The retrospective study was conducted at the Indus Hospital, Badin, The prospective study was conducted at the vaccination unit of a university hospital in Tekirdag, Turkey, from January to February 2021, and comprised healthcare professionals who came for receiving the second dose of the coronavirus disease-2019 inactivated severe acute respiratory syndrome coronavirus 2 vaccine 28 days after the first dose. Data was analysed using SPSS 18. RESULTS: Of the 1088 subjects, 714(65.6%) were female with mean age 29.85±9.2 years and 374(34.4%) were male with mean age 29.57±9.85 years. Overall, local pain in the vaccinated area 495(45.5%), fatigue 266(24.4%), headache 261(23.9%) and muscle pain 197(18.1%) were very common adverse effects. CONCLUSIONS: Inactivated severe acute respiratory syndrome coronavirus 2 vaccine was found to be safe.


Subject(s)
COVID-19 Vaccines , COVID-19 , Health Personnel , Adult , Female , Humans , Male , Young Adult , Antibodies, Viral , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Prospective Studies , Retrospective Studies , SARS-CoV-2 , Vaccines, Inactivated/adverse effects
9.
Russian Journal of Infection & Immunity ; 12(4):688-700, 2022.
Article in Russian | Academic Search Complete | ID: covidwho-2040490

ABSTRACT

In the context of the global spread of the new coronavirus infection, studies aimed at investigating formation of anti-infectious and post-vaccination immunity are of special importance, which is necessary to prevent and reduce morbidity and mortality due to SARS-CoV-2 infection. Purpose: to assess anti-infectious immunity against SARSCoV-2 in various forms of the disease and development of post-vaccination humoral reactions in medical workers of the perinatal center. Materials and methods. A study of blood serum was carried out to assess SARS-CoV-2-specific IgM and IgG antibodies in 119 medical workers recovered after COVID-19, divided into groups based on the disease severity (mild, moderate and asymptomatic), as well as in 62 vaccinated employees, divided into groups according to age. Semi-quantitative measurement of virus-specific antibodies was carried out by ELISA with test systems “SARS-CoV2-IgG-ELISA-BEST” and “SARS-CoV-2-IgM-ELISA-BEST”. Statistical processing of the research results was carried out using Microsoft Excel 2010 and Statistica 6. Quantitative characteristics were presented as median (ME), lower and upper quartiles (LQ1-UQ3);qualitative parameters - as absolute value and relative number (%). Difference between groups was analyzed by using the χ2 test (qualitative) and the Mann–Whitney U-test (quantitative). Results. The results of the study showed that the majority of employees with a moderate-severe form of SARS-CoV-2 had a high level of IgG (PR - a positivity rate of more than 9.0 arbitrary units) 9 months after the disease compared to those who suffered from mild or asymptomatic (83.3% versus 25.8% and 13.3%, p < 0.017) infection. The duration of IgG circulation after former illness had no relation to its severity and patient age. The effectiveness of the primary vaccination “Sputnik V” and revaccination with “Sputnik Light” and “KoviVak” was 100% after inoculating the vaccine second component. The lowest level of antibodies after the first vaccination is recorded in persons over 60 years old (1.48 (1.12–3.25 versus PR = 8.48 (5.78–10.11) and 9.27 (5.84–10.31) arbitrary units, p < 0.017)), in comparison with young and middle-age subjects. The speed SARS-CoV-2 elimination of IgG at 6, 9 or more months after vaccination depends on relevant initial peak antibody concentration. Subjects who were initially vaccinated with the KoviVac vaccine, IgG was not detected 2 months after vaccination. The protective effect of “Sputnik V”, “Sputnik Light”, “KoviVac” after re-infection with SARS-CoV-2 averages 71.2%. Conclusion. Thus, the results obtained on assessing anti-infectious and post-vaccination immunity against SARS-CoV-2 emphasize the need for further studies on a larger patient cohort, especially in those with asymptomatic infection as well as the elderly subjects. (English) [ FROM AUTHOR] Ð’ условиях глобального распространения новой коронавирусной инфекции особую значимость приобретают исследования, направленные на изучение формирования противоинфекционного и поствакцинального иммунитета, что является необходимым для предотвращения и снижения заболеваемости и смертности от SARS-CoV-2. Цель: оценить противоинфекционный иммунитет к SARS-CoV-2 при различных формах заболевания и развитие поствакцинальных гуморальных реакций у медицинских работников перинатального центра. Материалы и методы. Проведено исследование сыворотки крови на определение специ фических антител IgM и IgG классов к SARS-CoV-2 у 119 медицинских работников, перенесших COVID-19 и разделенных на группы в зависимости от тяжести течения заболевания (легкое, умеренное и бессимптомное), а также у 62 сотрудников, прошедших вакцинацию и разделенных на группы в зависимости от возраста. Полуколичественное определение антител осуществляли методом ИФА с использованием тест-систем «SARS-CoV-2-IgG-ИФА-БЕСТ» и «SARS-CoV-2-IgÐœ-ИФА-БЕСТ». Статистическую обработку результатов иcследования проводили с использованием программ «Microsoft Excel 2010» и Statistica 6. Количественные признаки представляли в виде медианы (МЕ), нижнего и верхнего квартилей (LQ1–UQ3);качественные- в виде абсолютного значения и относительного числа (%). Различия между группами устанавливали при помощи критерия χ2 (качественные) и Манна–Уитни (Mann–Whitney U-test) - количественные. Результаты. Результаты исследования показали, что у большинства сотрудников со среднетяжелой формой SARS-CoV-2 регистрируется более высокий уровень IgG (КП - коэффициент позитивности более 9,0 у.е.) спустя 9 месяцев после заболевания, чем у тех, кто переболел в легкой или бессимптомной форме (83,3% против 25,8% и 13,3%, Ñ€ < 0,017). Длительность циркуляции IgG после перенесенного заболевания не зависит от степени тяжести и возраста. Эффективность первичной вакцинации «Спутник V» и ревакцинации «Спутник Лайт» и «КовиВак» составляет 100% после введения второго компонента. Наименьший уровень антителпосле первой вакцинации регистрируется у лиц старше 60 лет (1,48 (1,12–3,25) против КП = 8,48 (5,78–10,11) и 9,27 (5,84–10,31) у.е., Ñ€ < 0,017) в сравнении с молодым и средним возрастом. Скорость элиминация IgG к SARS-CoV-2 через 6, 9 и более месяцев после проведения вакцинации зависит от их нач °Ð»ÑŒÐ½Ð¾Ð¹ пиковой концентрации. У первично привитых вакциной «КовиВак» IgG через 2 месяца после вакцинации не определяются. Протективный эффект «Спутник V», «Спутник Лайт», «КовиВак» от повторного заражения новой коронавирусной инфекции в среднем составляет 71,2%. Заключение. Таким образом, полученны результаты по оценке противоинфекционного и поствакцинального иммунитета к SARS-CoV-2 подчеркивают необходимость проведения дальнейших исследований на большей когорте пациентов, в особенности у лиц с бессимптомным течением инфекции и пожилых людей. (Russian) [ FROM AUTHOR] Copyright of Russian Journal of Infection & Immunity is the property of National Electronic-Information Consortium and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

10.
J Immunol Methods ; 506: 113293, 2022 07.
Article in English | MEDLINE | ID: covidwho-2000542

ABSTRACT

BACKGROUND: Real-world population studies have shown waning immunity, over time, after receiving the two doses of the BNT162b2 COVID-19 vaccine. Studies reporting the long-term humoral response are important to drive future vaccination strategies like the introduction of the booster dose. Yet, available literature on long follow-up periods is scarce. Covidiagnostix is a multicenter study aiming to assess the antibody response in >1000 healthcare professionals (HCPs) who received the BNT162b2 vaccine. METHODS: Serum was tested at time-0 (T0), before the first dose and then at T1, T2, T3 and T4, respectively, 21, 42, 177 and 302 days after T0. Antibodies against the SARS-CoV-2 nucleocapsid-protein were measured to assess SARS-CoV-2 infections, whereas antibodies against the receptor-binding domain of the spike protein were measured to assess vaccine response. RESULTS: The antibody titer observed 10 months post-vaccination showed a decrease of approximately 80% from the peak measured at T2, yet the median titer of the seronegatives HCPs was still higher than seropositives before vaccination. We identified 12 post-vaccination infected HCPs within 6 months after receiving the first dose and another 12 post-vaccination infected HCPs between 6 and 10 months post-vaccination. CONCLUSION: Vaccination induced a humoral response which is well detectable even 10 months post-vaccination. Yet a high anti-spike serum antibody titer does not guarantee protection from infection. Differences in symptomatology between SARS-CoV-2 infections occurred within the first 6 months post-vaccination and the following 4 months, and differences in COVID-19 prevalence and vaccination coverage observed in these two time intervals were consistent with a decrease in vaccine efficacy 6 months after receiving the first dose.


Subject(s)
COVID-19 , Viral Vaccines , Antibodies, Viral , BNT162 Vaccine , COVID-19/prevention & control , COVID-19 Vaccines , Delivery of Health Care , Humans , Kinetics , SARS-CoV-2
11.
BMC Neurol ; 22(1): 309, 2022 Aug 22.
Article in English | MEDLINE | ID: covidwho-2002129

ABSTRACT

BACKGROUND: To prevent the spread of the novel coronavirus disease 2019 (COVID-19) infection, various vaccines have been developed and used in a large number of people worldwide. One of the most commonly used vaccines is the mRNA vaccine developed by Moderna. Although several studies have shown this vaccine to be safe, the full extent of its side effects has not yet been known. Miller-Fisher syndrome (MFS) is a rare condition that manifests ophthalmoplegia, ataxia, and loss of tendon reflexes. It is a subtype of Guillain-Barré syndrome and an immune-mediated disease related to serum IgG anti-GQ1b antibodies. Several vaccines including those for COVID-19 have been reported to induce MFS. However, there have been no reports of MFS following Moderna COVID-19 vaccine administration. CASE PRESENTATION: A 70-year-old man was referred to our hospital due to diplopia that manifested 1 week after receiving the second Moderna vaccine dose. The patient presented with restricted abduction of both eyes, mild ataxia, and loss of tendon reflexes. He was diagnosed with MFS based on his neurological findings and detection of serum anti-GQ1b antibodies. The patient was administered intravenous immunoglobulin, and his symptoms gradually improved. Five days after admission, the patient showed peripheral facial paralysis on the right side. This symptom was suggested to be a delayed onset of peripheral facial nerve palsy following MFS that gradually improved by administration of steroids and antiviral drugs. CONCLUSION: There have been no previous reports of MFS after Moderna COVID-19 vaccination. This case may provide new information about the possible neurological side effects of COVID-19 vaccines.


Subject(s)
2019-nCoV Vaccine mRNA-1273 , COVID-19 , Facial Paralysis , Miller Fisher Syndrome , 2019-nCoV Vaccine mRNA-1273/adverse effects , Aged , COVID-19/complications , Facial Nerve/physiopathology , Facial Paralysis/chemically induced , Humans , Male , Miller Fisher Syndrome/chemically induced , Miller Fisher Syndrome/diagnosis , Vaccination/adverse effects
12.
Digit Health ; 8: 20552076221109530, 2022.
Article in English | MEDLINE | ID: covidwho-1957030

ABSTRACT

Vaccination for the COVID-19 pandemic has raised serious concerns among the public and various rumours are spread regarding the resulting illness, adverse reactions, and death. Such rumours can damage the campaign against the COVID-19 and should be dealt with accordingly. One prospective solution is to use machine learning-based models to predict the death risk for vaccinated people by utilizing the available data. This study focuses on the prognosis of three significant events including 'not survived', 'recovered', and 'not recovered' based on the adverse events followed by the second dose of the COVID-19 vaccine. Extensive experiments are performed to analyse the efficacy of the proposed Extreme Regression- Voting Classifier model in comparison with machine learning models with Term Frequency-Inverse Document Frequency, Bag of Words, and Global Vectors, and deep learning models like Convolutional Neural Network, Long Short Term Memory, and Bidirectional Long Short Term Memory. Experiments are carried out on the original, as well as, a balanced dataset using Synthetic Minority Oversampling Approach. Results reveal that the proposed voting classifier in combination with TF-IDF outperforms with a 0.85 accuracy score on the SMOTE-balanced dataset. In line with this, the validation of the proposed voting classifier on binary classification shows state-of-the-art results with a 0.98 accuracy.

13.
Health Sci Rep ; 5(4): e742, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1935686

ABSTRACT

Background and Aims: Fever after coronavirus disease 2019 (COVID-19) vaccination is generally a mild and benign event, but can cause excessive anxiety in younger adults. This study aimed to find key factors that include allergic diseases or physique that determine fever after vaccination. Methods: We conducted an observational cohort study in our hospital to assess post-COVID-19 vaccination fever from April to June 2021. A total of 153 medical personnel aged 22-86 years of age were involved in the study to receive two doses, intramuscularly 21 days apart, of the Pfizer-BioNTech COVID-19 vaccine (30 µg per dose). Vaccination records were taken more than 72 h after vaccination. Clinical and laboratory variables (age, sex, allergy history, weight, height, serum hemoglobin concentration, and these derivatives) were examined by multivariable logistic regression analysis using the peak axillary temperature in the 4-day period after the second vaccination as a dependent variable. Results: No serious safety problems were detected. The incidence of a postsecond vaccination fever of 37.3°C or above was 29.4%. Logistic regression analysis found age, history of perennial allergic rhinitis, body surface area, body weight, percent overweight, and serum hemoglobin concentration as independent predictors of postvaccination fever. The characteristics of this individual were incorporated into the numerical model of human thermoregulation. The evaluation of this model had a sensitivity of 66.1% and a specificity of 90.7% in the detection of postvaccination fever. The multiple coefficient of determination (R 2) was 0.410. Conclusion: The COVID-19 vaccine induced higher rates of fever during the 4-day period after the second vaccination. Younger age, part of the allergy history, small and light body, and concentrated blood were associated with postvaccination fever.

14.
IDCases ; 29: e01569, 2022.
Article in English | MEDLINE | ID: covidwho-1935400

ABSTRACT

The exact pathogenesis of Multisystem Inflammatory Syndrome in Children (MIS-C) is unknown. Reports on response to vaccination in children who had MIS-C are lacking. Using prospectively enrolled children, we report on humoral immune responses prior to and after SARS-CoV-2 immune rechallenge. Recurrent auricular chondritis was also noted in one child.

15.
Indian Journal of Radiology and Imaging ; 2022.
Article in English | Web of Science | ID: covidwho-1937478

ABSTRACT

In the era of this pandemic, without any proper and efficacious availability of antiviral agents against the novel coronavirus disease 2019 (COVID-19), vaccines have come as a hope for humankind. Although adverse reactions are common after getting the COVID-19 vaccine, serious or life-threatening side effects are very uncommon in these new emergency-approved vaccines. In this case report, we describe an unusual case of adverse reaction in a patient who received the COVID-19 vaccination. The patient who received the COVID-19 vaccination presented with progressive right lower limb pain and swelling, which further progressed to bilateral shoulder pain and swelling. Ultrasonography, Doppler, and magnetic resonance imaging of right lower limb were done for the patient.

16.
Viral Immunol ; 35(5): 386-389, 2022 06.
Article in English | MEDLINE | ID: covidwho-1931785

ABSTRACT

The kinetics of postvaccination serum anti-Spike IgG concentration were determined in 1,541 health care workers (Sant'Andrea Hospital of Rome, Italy) with no prior infection by SARS-COV-2. Anti-Spike IgG were measured at 3, 12, and 24 weeks after the completion of the primary vaccine cycle (two doses of the BNT162b2 vaccine by Biontech/Pfizer) and 3 weeks apart a third BNT162b2 dose. Stratification of the study population by age (decades from 21-30 to 61-70) highlighted that 24 weeks after cycle completion all age groups had an order of magnitude reduction in serum IgG titers. Considering older adults (age 61-70), they had significantly lower serum IgG titers at each time point compared with younger people, except after the booster dose, which induced similar and elevated IgG titers despite the age.


Subject(s)
COVID-19 , Vaccines , Aged , Antibodies, Viral , BNT162 Vaccine , COVID-19/prevention & control , Health Personnel , Humans , Immunoglobulin G , Middle Aged , SARS-CoV-2
17.
Indian J Otolaryngol Head Neck Surg ; 74(Suppl 2): 3293-3303, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-1930555

ABSTRACT

India currently ranks the highest in the world with over 3.86 lakhs new COVID-19 cases per day. With a spike in the number of cases in the second wave of COVID-19 in 2021 compared to the first wave of the outbreak in 2020, there have been varied clinical manifestations among masses. This study aimed to determine the changing trends in prevalence of COVID-19 symptoms during the pandemic. A cross-sectional study among 166 individuals was carried out using a self-designed survey-based questionnaire. Two groups were made on the basis of symptoms and compared: Group A- patients who tested COVID-19 positive in 2020 and Group B- patients who tested COVID-19 positive in 2021. 130 participants (78.31%) had tested positive for COVID-19, out of which 110 (84.62%) were symptomatic and 20 (15.38%) were asymptomatic. Fever was the most common presenting symptom (27.69%) followed by difficulty in breathing (24.62%). Group A individuals (n = 37), reported fever as the most common presenting symptom (45.95%), followed by body ache (13.51%); while those in Group B (n = 93) reported difficulty in breathing (33.33%) followed by fever (20.43%). The most common general symptoms were fever and difficulty in breathing while sore throat, cough and anosmia were the most common ENT symptoms. 57.83% had been vaccinated out of which 38.55% experienced symptoms post-vaccination. The prevalence of symptoms in the first and second wave of the pandemic can help in better understanding of the changing symptomatology of SARS-CoV-2 virus.

18.
J Appl Microbiol ; 133(3): 1969-1974, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1927599

ABSTRACT

AIMS: Presence of anti-S1 region of SARS-CoV-2 spike protein was analysed, at two and eight months, in 477 immunocompetent healthcare workers in Zaragoza, Spain, vaccinated with mRNA-1273 (Moderna) or BNT162b2 (Pfizer). METHODS AND RESULTS: Antibody analysis was performed with Alinity i System (Abbott). At 2 months, 100% of vaccinated had anti-S1 IgG (mean = 13,285 AU ml-1 ). This value was significantly higher with Moderna (18,192 AU ml-1 ) than with Pfizer (10,441 AU ml-1 ). The mean value of anti-S1 IgG after vaccination was significantly higher in patients with than without previous infection (18,539 vs. 7919 AU ml-1 ); in both groups was significantly higher with Moderna than with Pfizer (21,881 vs. 15,733 AU ml-1 and 11,949 vs. 6387 AU ml-1 ), respectively. At 8 months, 100% of patients were IgG positive, with higher levels with Moderna than with Pfizer. Nevertheless, in ensemble of cases, a mean decrease of antibody levels of 11,025 AU ml-1 was observed. CONCLUSION: At 2 and 8 months after vaccination, IgG response persists with both vaccines but with important decrease which suggests the need for revaccination. SIGNIFICANCE AND IMPACT OF STUDY: The study contributes to know the immune status after vaccination with two of more used anti-SARS-CoV-2 vaccines. This knowledge is important for establishing the best vaccination strategy.


Subject(s)
COVID-19 Vaccines , COVID-19 , Immunity, Humoral , 2019-nCoV Vaccine mRNA-1273 , Antibodies, Viral , BNT162 Vaccine , COVID-19/prevention & control , COVID-19 Vaccines/immunology , Health Personnel , Humans , Immunoglobulin G , SARS-CoV-2 , Spain , Spike Glycoprotein, Coronavirus/immunology , Vaccination
19.
Mult Scler Relat Disord ; 66: 104035, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-1914840

ABSTRACT

During the coronavirus disease 2019 (COVID-19) pandemic, mass vaccination was a beneficial strategy in many countries. Nevertheless, reports of serious complications such as postvaccination neuromyelitis optica spectrum disorder (NMOSD) raised concerns about the safety of vaccines. Anamnart and colleagues explained postvaccination NMOSD following different vaccines, including COVID-19. To emphasize the message of this article, in this letter, we present a unique case of postvaccination NMOSD with a fulminant and fatal course, which may show a plausible relationship between COVID-19 vaccination and triggering anti-aquaporin-4 antibody (AQP4-Ab).


Subject(s)
COVID-19 Vaccines , COVID-19 , Neuromyelitis Optica , Humans , Aquaporin 4 , Autoantibodies , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Neuromyelitis Optica/complications , Vaccination/adverse effects
20.
Am J Ophthalmol Case Rep ; 27: 101654, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1914113

ABSTRACT

Purpose: To describe a unique case of bilateral cataract formation in the setting of multisystem inflammation after the 1st dose of the BNT162b2 mRNA COVID-19 vaccination. Observations: A previously healthy 20-year-old male developed intumescent bilateral cataracts leading to visual decline from 20/20 to 20/300-20/400 in each eye, likely from systemic inflammation after vaccination. Conclusion and importance: This is the first reported case of cataract formation following a COVID-19 vaccine. While ocular adverse effects associated with COVID-19 vaccination are rare, it is important to raise awareness of these entities amongst medical providers as the COVID-19 pandemic continues and vaccinations become widespread.

SELECTION OF CITATIONS
SEARCH DETAIL